| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/107385802237176 |
| P698 | PubMed publication ID | 12374432 |
| P2093 | author name string | Husseini K Manji | |
| Todd D Gould | |||
| P2860 | cites work | Evidence-Based Health Policy---Lessons from the Global Burden of Disease Study | Q53681960 |
| Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. | Q54415298 | ||
| GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis | Q24309150 | ||
| Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation | Q24528506 | ||
| A molecular mechanism for the effect of lithium on development | Q24629067 | ||
| Casein kinase iepsilon in the wnt pathway: regulation of beta-catenin function | Q24653937 | ||
| CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium | Q24680427 | ||
| A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catenin | Q28115262 | ||
| Positional syntenic cloning and functional characterization of the mammalian circadian mutation tau. | Q28142534 | ||
| Circadian rhythm genetics: from flies to mice to humans | Q28145351 | ||
| Glycogen synthase kinase-3: properties, functions, and regulation | Q28212200 | ||
| Mood stabilizers, glycogen synthase kinase-3beta and cell survival | Q28216404 | ||
| The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation | Q28244304 | ||
| Neural and developmental actions of lithium: a unifying hypothesis | Q28254375 | ||
| double-time is a novel Drosophila clock gene that regulates PERIOD protein accumulation | Q28277205 | ||
| Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling | Q28373447 | ||
| Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity | Q28378569 | ||
| Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons | Q28565001 | ||
| WNT-7a induces axonal remodeling and increases synapsin I levels in cerebellar neurons | Q28586422 | ||
| The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape | Q28613516 | ||
| beta-Catenin is essential for patterning the maternally specified animal-vegetal axis in the sea urchin embryo | Q28776528 | ||
| Wnt signaling: a common theme in animal development | Q29547527 | ||
| Mechanisms of Wnt signaling in development | Q29547537 | ||
| The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3 | Q29614380 | ||
| Molecular analysis of mammalian circadian rhythms | Q29618036 | ||
| Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells | Q29618245 | ||
| Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus | Q29620188 | ||
| Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription | Q31462537 | ||
| Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry | Q31805313 | ||
| Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression | Q31833575 | ||
| Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. | Q31855623 | ||
| Anti-bipolar therapy: mechanism of action of lithium | Q33596950 | ||
| Sleep deprivation in depression: what do we know, where do we go? | Q33718672 | ||
| Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? | Q33745706 | ||
| Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge | Q33750436 | ||
| Historical perspectives and natural history of bipolar disorder | Q33920209 | ||
| Signaling: cellular insights into the pathophysiology of bipolar disorder | Q33920217 | ||
| Neuroimaging studies of mood disorders | Q33924331 | ||
| Roles of Wnt proteins in neural development and maintenance | Q33941597 | ||
| Regulation of glycogen synthase kinase 3beta and downstream Wnt signaling by axin | Q33959834 | ||
| Neuroplasticity and cellular resilience in mood disorders | Q34111006 | ||
| Molecular components of the circadian system in Drosophila | Q34142196 | ||
| Signaling through beta-catenin and Lef/Tcf | Q34158484 | ||
| Lithium and synaptic plasticity. | Q34185371 | ||
| Searching high and low: a review of the genetics of bipolar disorder | Q34186927 | ||
| Sleep reduction as a final common pathway in the genesis of mania | Q34191452 | ||
| Molecular targets of lithium action | Q34192797 | ||
| Wnt signalling: a theme with nuclear variations | Q34194535 | ||
| Regulation of GSK-3: a cellular multiprocessor | Q34299875 | ||
| Casein kinase I: from obscurity to center stage | Q34313530 | ||
| Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx | Q34458296 | ||
| Ectopic expression of the proto-oncogene int-1 in Xenopus embryos leads to duplication of the embryonic axis. | Q34507567 | ||
| Overexpression of components of the Frizzled-Dishevelled cascade results in apoptotic cell death, mediated by beta-catenin | Q34514475 | ||
| Endophenotypes in bipolar disorder | Q34626051 | ||
| The molecular basis of Turcot's syndrome | Q34662365 | ||
| Neuroprotective effects of lithium in cultured cells and animal models of diseases. | Q34692758 | ||
| Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection | Q34692767 | ||
| Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats | Q34749667 | ||
| Signaling networks in the pathophysiology and treatment of mood disorders | Q34778245 | ||
| Rhythms and the pharmacology of lithium | Q35217626 | ||
| Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons | Q35563894 | ||
| APC mutations in sporadic medulloblastomas | Q35745470 | ||
| Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription | Q36370019 | ||
| N-acetylaspartate in neuropsychiatric disorders | Q36787721 | ||
| Lithium and electroconvulsive therapy: adversaries, competitors, allies? | Q36926298 | ||
| The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis | Q38137418 | ||
| The circadian system and the therapeutics of the affective disorders | Q40551070 | ||
| Lithium and brain signal transduction systems | Q40719294 | ||
| Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors | Q40795419 | ||
| Wnt signaling to beta-catenin involves two interactive components. Glycogen synthase kinase-3beta inhibition and activation of protein kinase C. | Q40888981 | ||
| The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. | Q40970988 | ||
| Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder | Q41724677 | ||
| Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands | Q41922155 | ||
| Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling | Q42032355 | ||
| Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium | Q42484847 | ||
| Glycogen synthase kinase 3 regulates cell fate in Dictyostelium | Q42487608 | ||
| Inactivation of glycogen synthase kinase-3 by epidermal growth factor is mediated by mitogen-activated protein kinase/p90 ribosomal protein S6 kinase signaling pathway in NIH/3T3 cells | Q42830614 | ||
| Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness | Q43509323 | ||
| 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). | Q43552091 | ||
| Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death | Q43560460 | ||
| The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. | Q43682742 | ||
| Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene | Q45345254 | ||
| Casein kinase I transduces Wnt signals | Q47069139 | ||
| A role for the segment polarity gene shaggy/GSK-3 in the Drosophila circadian clock | Q47070465 | ||
| The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness | Q47284701 | ||
| Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway | Q47762057 | ||
| Abnormalities of Wnt signalling in schizophrenia--evidence for neurodevelopmental abnormality | Q47959350 | ||
| Increased expression of Wnt-1 in schizophrenic brains | Q48149287 | ||
| Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action | Q48153911 | ||
| Subgenual prefrontal cortex abnormalities in mood disorders | Q48725544 | ||
| Increase in AP-1 transcription factor DNA binding activity by valproic acid | Q48773462 | ||
| Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. | Q48925700 | ||
| Twenty-four-hour profiles of body temperature and plasma TSH in bipolar patients during depression and during remission and in normal control subjects | Q48953527 | ||
| Activation of the Wnt signaling pathway: a molecular mechanism for lithium action | Q48958687 | ||
| Human morbid genetics revisited: relevance of epigenetics. | Q51969175 | ||
| Synergistic effects of tetrahydroaminoacridine and lithium on cholinergic function after excitotoxic basal forebrain lesions in rat. | Q51979224 | ||
| Lithium: a brake in the rising cost of mental illness. | Q52104831 | ||
| TCF is the nuclear effector of the beta-catenin signal that patterns the sea urchin animal-vegetal axis. | Q52171941 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bipolar disorder | Q131755 |
| P304 | page(s) | 497-511 | |
| P577 | publication date | 2002-10-01 | |
| P1433 | published in | The Neuroscientist | Q7753449 |
| P1476 | title | The Wnt signaling pathway in bipolar disorder | |
| P478 | volume | 8 |
| Q26786354 | A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates |
| Q40091387 | A regulatory circuit mediating convergence between Nurr1 transcriptional regulation and Wnt signaling |
| Q33284843 | A systematic review of existing data on long-term lithium therapy: neuroprotective or neurotoxic? |
| Q97418693 | Advances toward precision medicine for bipolar disorder: mechanisms & molecules |
| Q28075617 | Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma |
| Q34506154 | Ankyrin-G regulates neurogenesis and Wnt signaling by altering the subcellular localization of β-catenin |
| Q34593873 | Association study of Wnt signaling pathway genes in bipolar disorder |
| Q28569321 | Bone morphogenetic protein 4 stimulates neuronal differentiation of neuronal stem cells through the ERK pathway |
| Q37184659 | Characterization of maleimide-based glycogen synthase kinase-3 (GSK-3) inhibitors as stimulators of steroidogenesis |
| Q44660823 | Chronic electroconvulsive seizure up-regulates beta-catenin expression in rat hippocampus: role in adult neurogenesis |
| Q36600788 | Circadian Rhythm Characteristics in Mood Disorders: Comparison among Bipolar I Disorder, Bipolar II Disorder and Recurrent Major Depressive Disorder |
| Q34452078 | Circadian rhythms, Wnt/beta-catenin pathway and PPAR alpha/gamma profiles in diseases with primary or secondary cardiac dysfunction |
| Q37492529 | Developmental exposure to valproic acid alters the expression of microRNAs involved in neurodevelopment in zebrafish |
| Q39547248 | Differential display RT-PCR reveals genes associated with lithium-induced neuritogenesis in SK-N-MC cells |
| Q36582366 | Diseases of Wnt signaling |
| Q34203814 | Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder? |
| Q37370726 | Effect of activation of canonical Wnt signaling by the Wnt-3a protein on the susceptibility of PC12 cells to oxidative and apoptotic insults. |
| Q35770186 | Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers |
| Q34626051 | Endophenotypes in bipolar disorder |
| Q36203441 | Epistasis network centrality analysis yields pathway replication across two GWAS cohorts for bipolar disorder |
| Q37159843 | Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers |
| Q39365286 | Expression of the zinc importer protein ZIP9/SLC39A9 in glioblastoma cells affects phosphorylation states of p53 and GSK-3β and causes increased cell migration. |
| Q90796921 | Fractal biomarker of activity in patients with bipolar disorder |
| Q24624069 | GSK-3: tricks of the trade for a multi-tasking kinase |
| Q50757557 | GSK-3β polymorphism discriminates bipolar disorder and schizophrenia: a systematic meta-analysis. |
| Q28476300 | GSK3beta regulates differentiation and growth arrest in glioblastoma |
| Q28533881 | Gene expression profiling of a hypoxic seizure model of epilepsy suggests a role for mTOR and Wnt signaling in epileptogenesis |
| Q35210243 | Gene expression profiling of peri-implant healing of PLGA-Li+ implants suggests an activated Wnt signaling pathway in vivo |
| Q38088822 | Gene regulation as a potential avenue for the treatment of neurodegenerative disorders |
| Q37526428 | Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application |
| Q39937420 | Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. |
| Q37702007 | Glycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma |
| Q42092190 | Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium |
| Q47641512 | Glycogen synthase kinase 3beta as a likely target for the action of lithium on circadian clocks |
| Q35187043 | Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice |
| Q35196646 | IFN-gamma mediates enhancement of HIV replication in astrocytes by inducing an antagonist of the beta-catenin pathway (DKK1) in a STAT 3-dependent manner. |
| Q30464459 | Identification of a glycogen synthase kinase-3β inhibitor that attenuates hyperactivity in CLOCK mutant mice |
| Q59792982 | Identification of potential genetic risk factors for bipolar disorder by whole-exome sequencing |
| Q44564336 | In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. |
| Q45259237 | Inhibition of phosphoglucomutase activity by lithium alters cellular calcium homeostasis and signaling in Saccharomyces cerevisiae. |
| Q47615913 | Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood. |
| Q91666170 | Lithium alters expression of RNAs in a type-specific manner in differentiated human neuroblastoma neuronal cultures, including specific genes involved in Alzheimer's disease |
| Q36559874 | Lithium inhibits tumor lymphangiogenesis and metastasis through the inhibition of TGFBIp expression in cancer cells |
| Q48406708 | Lithium response viewed as a biomarker to predict developmental psychopathology in offspring with bipolar disorder: a commentary. |
| Q79774804 | Mitochondrial dysfunction and psychiatric disorders |
| Q37072337 | Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. |
| Q36370360 | Mode of action: inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin--developmental effects of valproic acid |
| Q37946881 | Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies |
| Q28565765 | Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression |
| Q36031634 | Mood stabilizer psychopharmacology |
| Q44989787 | Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. |
| Q36281844 | Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics |
| Q46102679 | Na+,K+-ATPase activity in an animal model of mania. |
| Q36401907 | Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets |
| Q37035241 | Neurobiology of bipolar disorder |
| Q52605230 | No association of Disrupted-in-Schizophrenia-1 variation with prefrontal function in patients with schizophrenia and bipolar disorder. |
| Q26742196 | Opposite Interplay between PPAR Gamma and Canonical Wnt/Beta-Catenin Pathway in Amyotrophic Lateral Sclerosis |
| Q38472991 | Protein profiles of Chinese white wax scale, Ericerus pela, at the male pupal stage by high-throughput proteomics |
| Q89608062 | Riluzole: a therapeutic strategy in Alzheimer's disease by targeting the WNT/β-catenin pathway |
| Q37850712 | Role of β-catenin/TCF-4 signaling in HIV replication and pathogenesis: insights to informing novel anti-HIV molecular therapeutics |
| Q41975361 | Selective growth inhibition by glycogen synthase kinase-3 inhibitors in tumorigenic HeLa hybrid cells is mediated through NF-κB-dependent GLUT3 expression |
| Q35934683 | Sex differences in DNA methylation may contribute to risk of PTSD and depression: a review of existing evidence |
| Q37118472 | Suggestive evidence for association of the circadian genes PERIOD3 and ARNTL with bipolar disorder |
| Q35234350 | Synaptic Wnt signaling-a contributor to major psychiatric disorders? |
| Q35824206 | The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing |
| Q24652979 | The Wnt-dependent signaling pathways as target in oncology drug discovery |
| Q36293345 | The behavioral actions of lithium in rodent models: leads to develop novel therapeutics |
| Q34018084 | The small molecule indirubin-3'-oxime activates Wnt/β-catenin signaling and inhibits adipocyte differentiation and obesity |
| Q34562614 | The underlying neurobiology of bipolar disorder |
| Q39239818 | Thermodynamics in cancers: opposing interactions between PPAR gamma and the canonical WNT/beta-catenin pathway |
| Q37607009 | Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder |
| Q28484912 | Valproic acid induces cutaneous wound healing in vivo and enhances keratinocyte motility |
| Q33391576 | Valproic acid induces differentiation and inhibition of proliferation in neural progenitor cells via the beta-catenin-Ras-ERK-p21Cip/WAF1 pathway |
| Q28482239 | Valproic acid induces hair regeneration in murine model and activates alkaline phosphatase activity in human dermal papilla cells |
| Q36404742 | WNTs tune up the neuromuscular junction |
| Q34088354 | Wnt2 expression and signaling is increased by different classes of antidepressant treatments |
| Q37190803 | Wnt3a is critical for endothelial progenitor cell-mediated neural stem cell proliferation and differentiation |
| Q55450116 | Wnts Promote Synaptic Assembly Through T-Cell Specific Transcription Factors in Caenorhabditis elegans. |
| Q38172119 | Wnts in adult brain: from synaptic plasticity to cognitive deficiencies |
Search more.